Anavex Life Sciences Corp (AVXL)

[nidan7500]

2014..thx

“We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, Alzheimer’s disease and Parkinson’s disease trials. It was a strategic decision to start the new clinical trials after genetic data were collected and analyzed. We are expecting to leverage these important findings to more precisely target patients based on specific genomic profiles that may be highly responsive to ANAVEX®2-73,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “This should allow us to improve upon existing trial designs and expedite other aspects of our clinical development program.”

My simple Interpretation of these points:

.Marker selection w/precision identifies who will/will not respond in future trials. Compared to old style shotguning -some will some won't..it happens.

.The strategy is based on things we learned and wish to leverage/validate so that we are able to narrow down the number of future non responders even as we treat those we are able to. This is a learning process. It would be great if one size fits all but that probably will not happen.

.It is just as important to know WHAT TO DO as it is the KNOW WHAT TO NOT DO.

. We do expect that future trials will continue to reduce the population of patients we cannot treat effectively.